Clincosm LogoSign in Get a demo

Evaluation the Growth Factors(IGF-1,IGFBP-3and HGH)in Patients With Chronic Liver Disease

Sponsor
Kaohsiung Medical University Chung-Ho Memorial Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT00679692
Collaborator
(none)
210
Enrollment
1
Location
18
Duration (Months)
11.7
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

BACKGROUND The insulin-like growth factor system (IGFs) plays an important role in cell growth and differentiation. Nevertheless, the roles played by insulin-like growth factor-1 (IGF-1), insulin-like growth factor binding protein-3 (IGFBP-3) and human growth hormone (HGH) in the progression of chronic liver disease remain to be elucidated and investigated.

METHODS The subjects in the present study included 60 healthy controls, 30 hepatitis patients, 60 liver cirrhosis patients and 60 untreated hepatocellular carcinoma patients. Blood was drawn by venipuncture into Venoject tubes. To find the possible correlations between liver damage and IGFs, serum IGF-1, GH, IGFBP-3 concentration and related biochemical parameters were measured. We used immunoradiometric assay to determine the levels of IGF-1, HGH and IGFBP-3 in serum.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    healthy controls:one blood sample (7.5 cc) hepatitis: three blood samples, at admission, at 3rd and 7-10th day of admission liver cirrhosis: two blood samples, at 1-2 years interval (7.5 cc/each session) hepatocellular carcinoma: three blood samples, before, 1 day after and at the 7th day of transcatheter arterial chembolizatiom

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    210 participants
    Time Perspective:
    Prospective
    Official Title:
    Insulin-Like Growth Factor-1,Insulin-Like Growth Factor Binding Protein-3 and Human Growth Hormone in Serum of Patients With Chronic Liver Disease and Possible Clinical Applications.
    Study Start Date :
    Sep 1, 2006
    Actual Primary Completion Date :
    Mar 1, 2008
    Actual Study Completion Date :
    Mar 1, 2008

    Arms and Interventions

    Arm Intervention/Treatment
    3:

    three arms for study

    Outcome Measures

    Primary Outcome Measures

      Eligibility Criteria

      Criteria

      Ages Eligible for Study:
      30 Years to 80 Years
      Sexes Eligible for Study:
      All
      Accepts Healthy Volunteers:
      Yes
      Inclusion Criteria:

      • Clinical diagnosis of Hepatocellular carcinoma

      • Must be primary Hepatocellular carcinoma and untreament

      Exclusion Criteria:
      • treatment Hepatocellular carcinoma

      Contacts and Locations

      Locations

      Site City State Country Postal Code
      1 Division of Radio immunoassay lab,Department of Nuclear Medical University Hospital,No.100 Tzyou 1st Road Kaohsiung Taiwan

      Sponsors and Collaborators

      • Kaohsiung Medical University Chung-Ho Memorial Hospital

      Investigators

      • Principal Investigator: chiou m Lin, Ms, Kaohsiung Medical University

      Study Documents (Full-Text)

      None provided.

      More Information

      Publications

      None provided.
      Responsible Party:
      , ,
      ClinicalTrials.gov Identifier:
      NCT00679692
      Other Study ID Numbers:
      • KMUH-IRB-950123
      • KMUH-IRB-950123
      First Posted:
      May 19, 2008
      Last Update Posted:
      May 19, 2008
      Last Verified:
      Jan 1, 2006
      Keywords provided by , ,
      GH,IGF-1, IGFBP-3
      Additional relevant MeSH terms:
      Liver Diseases
      Liver Cirrhosis

      Study Results

      No Results Posted as of May 19, 2008